TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
39.49
+1.50 (3.95%)
Apr 23, 2025, 4:00 PM EDT - Market closed
TG Therapeutics Revenue
In the year 2024, TG Therapeutics had annual revenue of $329.00M with 40.80% growth. TG Therapeutics had revenue of $108.19M in the quarter ending December 31, 2024, with 146.04% growth.
Revenue (ttm)
$329.00M
Revenue Growth
+40.80%
P/S Ratio
17.44
Revenue / Employee
$973,385
Employees
338
Market Cap
5.74B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 329.00M | 95.34M | 40.80% |
Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
Dec 31, 2020 | 152.00K | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
TGTX News
- 13 days ago - TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - GlobeNewsWire
- 16 days ago - TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals - GlobeNewsWire
- 4 weeks ago - Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher - Benzinga
- 5 weeks ago - Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel - Seeking Alpha
- 5 weeks ago - TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials - Seeking Alpha
- 6 weeks ago - TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter - Seeking Alpha
- 6 weeks ago - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - GlobeNewsWire
- 7 weeks ago - Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025 - Invezz